Abstract 5089
Background
The variability of clinical response to immune checkpoint inhibitors in RCC patients makes necessary the discovery of predictive biomarkers for patient selection. Emerging evidence has revealed a multitude of silenced genes and deregulated signalling pathways. These findings point towards extensive microRNAs (miRNAs) regulation and imply epigenetic reprogramming as a key feature of RCC. The aim of this study was to analyze the peripheral lymphocyte miRNA expression profile in metastatic RCC patients undergoing nivolumab treatment, to identify a lymphocyte miRNA signature specifically expressed in patients with partial or complete response (RP; RC) >12 months.
Methods
miRNAs were isolated from peripheral lymphocytes of 18 mRCC patients treated with nivolumab as 2nd line. The blood samples were collected before starting treatment (T0) and after 4 weeks (T1). The expression profile of 377 miRNAs was analyzed, with a cut off of fold change >2 for up-regulated and <0.3 for down-regulated miRNAs. Patients were divided into 2 groups: i) patients with disease progression (PD) within 6 months of treatment (P1); ii) patients with durable response (SD, RP, RC) >12 months (P2).
Results
Microarray analysis showed several differentially expressed miRNAs in peripheral lymphocytes of P1 and P2, involved in RCC signaling pathways such as VHL-HIF, PI3K/Akt, PTEN and WNT-β-catenin. Surprisingly, patients with RC > 12 months showed a subset of 8 miRNAs (miR-24, miR-22, miR-99a, miR-708, miR-339, miR-335, miR-214, miR-194) specifically induced by nivolumab treatment. These miRNAs are silenced or downregulated in RCC. This could explain the exceptional up-regulation in long-responder patients, evident already after 4 weeks of treatment.
Conclusions
Our study for the first time analyzed the miRNA expression profile in peripheral lymphocytes and showed the exceptional up-regulation of a specific subset of miRNA only in RCC patients with durable (<12 months) and complete response to nivolumab treatment. These findings could help to identify novel predictive biomarkers urgently needed to guide clinical decision-making in RCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Department of Surgical, Oncological and Oral Sciences, University of Palermo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract